Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009

Table 1 Summary of the terms used singly or in combination for evidence acquisition

Primary MeSH terms	Secondary MeSH terms (Epidemiology, diagnosis)	Secondary MeSH terms (treatment, palliation)
Cholangiocarcinoma(s)	Epidemiology	Hepatectomy
Adenocarcinoma(s)	Classification	Resection
Carcinoma(s)	Diagnosis	Therapeutic(s)
Bile duct neoplasm(s)	Differential diagnosis	Treatment outcome(s)
Biliary tract neoplasm(s)	Early diagnosis	Surgery
Common bile duct neoplasm(s)	Risk factor(s)	Transplantation
Liver neoplasm(s)	Diagnostic imaging	Biliary tract
Bile duct(s)	Magnetic resonance imaging	Surgical procedures
Common bile duct	Endosonography	Liver transplantation
Intrahepatic bile duct(s)	Ultrasonography	Organ transplantation
Extrahepatic bile duct(s)	Emission computed tomography	Clinical trial
Biliary tract disease(s)	Radionuclide imaging	Controlled clinical trial(s)
Bile duct disease(s)	Positron emission tomography	Randomized controlled trial(s)
	X-ray	Clinical trial (phase I)
	Computed tomography	Clinical trial (phase II)
	Biopsy (needle)	Clinical trial (phase III)
	Biopsy (fine needle)	Clinical trial (phase IV)
	Cytology	Drug therapy
	Cytodiagnosis	Chemotherapy
	Tumor markers (biological) antigen(s)	Adjuvant
	Carcinoembryonic antigen	Antineoplastic agent(s)
	Ca 19-9 antigen	Combined modality therapy
	Ca 125 antigen	Antineoplastic
	Endoscopic retrograde cholangiopancreatography	Combined chemotherapy protocols
	Cholangiography	Neoadjuvant therapy
	In situ hybridization	Radiotherapy
	Fluorescence in situ hybridization	Adjuvant embolization
	Nucleic acid hybridization	Portal vein embolization
	Computed assisted image processing	Drainage
		Cholestasis
		Obstructive jaundice